New Evidence of the Impact of the National Drug Price Negotiation Policy on the Availability, Utilization, and Cost of Anticancer Medicines in China: An Interrupted Time Series Study
The 2021 NDPN policy has notably enhanced the availability and utilization of anticancer medications in China while reducing their cost, in line with the policy's objectives. However, continuous monitoring is essential to ensure sustained access and to tackle regional disparities in drug utilization.
Authors
- Xingyuan Gao (ORCID: https://orcid.org/0000-0002-3204-0336)
- Tiansi Zhang
- Lingli Zhang (ORCID: https://orcid.org/0000-0001-7764-9973)
- Xin Li (ORCID: https://orcid.org/0000-0003-3951-8061)
- Yuyang Sun (ORCID: https://orcid.org/0009-0004-0331-2533)
- Man Yu (ORCID: https://orcid.org/0000-0003-2777-3620)
- Changqing Wang (ORCID: https://orcid.org/0000-0002-5323-1713)
Institutions
- China Pharmaceutical University (CN)
- Simcere Pharmaceutical (China) (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Risk Management and Healthcare Policy
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/rmhp.s473846
- Citations
- 2
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- National Natural Science Foundation of China